

Client
Gurugram
Pathkind Diagnostics Pvt. Ltd.
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

Processed By
Pathkind Diagnostics Pvt. Ltd.
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

Name : Mr. CL138	Billing Date : 07/07/2023 12:18:18
Age : 35 Yrs	Sample Collected on : 10/07/2023 10:01:31
Sex : Male	Sample Received on : 10/07/2023 11:02:13
P. ID No. : P1000100012620	Report Released on : 10/07/2023 15:38:25
Accession No : 10002304676	Barcode No. : 10002304676
Referring Doctor : Self	Ref no. :
Referred By :	

Report Status - Final

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

BIOCHEMISTRY

# Cyclosporine <i>Sample: Whole Blood EDTA</i>	450.00	Trough Level (C0): 100 - 400 Renal transplant (C2): 800 - 1700 Liver Transplant (C2): 600 - 1000	ng/ml
--	--------	--	-------

Cyclosporine

LCMS is considered the most sensitive and specific technology for Therapeutic drug monitoring (TDM). It is commonly used to maintain drug levels within the concentration range in which the drug exerts its clinical effect with minimal adverse re Cyclosporine is a lipophilic polypeptide used to prevent rejection after solid organ transplantation; it suppresses T-cell activation inhibiting calcineurin to decrease interleukin-2 (IL-2) production. There is substantial interpatient variability in absorption, half-life, and other pharmacokinetic parameters. Preferred therapeutic ranges may vary by transplant type and protocols used. Therapeutic ranges are based on specimens drawn at trough (C0) (ie, immediately before the next scheduled dose). Blood drawn at other times will yield higher results. This test may also be used to analyze cyclosporine levels 2 hours (C2) after dosing; trough therapeutic ranges (C0) do not apply to post dose specimens. Target steady-state trough concentrations vary depending on the type of transplan immunosuppression, clinical/institutional protocols, and time post-transplant. Results should be interpreted in conjunction with thi clinical information and any physical signs/symptoms of rejection/toxicity.

** End of Report**



Dr. Daipayan Ghosh
Scientist



Dr. Aarti Khanna Nagpal
DNB (Pathology)
Senior Consultant

